The DOI matches its Crossref record.
A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
Abstract
Between 1978 and 1981, 463 evaluable postmenopausal patients 65 years of age or younger with operable breast cancer and metastases in axillary lymph nodes were entered in Ludwig Breast Cancer Study III (Ludwig III) and randomly allocated to receive chemoendocrine therapy with cyclophosphamide, methotrexate, 5-fluorouracil, low-dose continuous prednisone, and tamoxifen (CMFp + T) for 12 monthly cycles, or endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year, or no adjuvant treatment after mastectomy (observation). At 60 months' median follow-up, the 5-year disease-free survival (DFS) rates were 59% for CMFp + T, 41% for p + T, and 31% for observation (P less than .0001), and the 5-year overall survival (OS) rates were 71% for CMFp + T, 64% for p + T, and 59% for observation (P = .16; CMFp + T v observation, P = .07). A new quality of life-oriented endpoint was defined to assist in the selection of therapeutic approach after surgery for postmenopausal patients: the time without symptoms of disease and subjective toxic effects of treatment (TWiST). Despite the larger initial discount due to subjective toxicity with chemoendocrine therapy, by 5 years postmastectomy the net difference in average TWiST for treated patients compared with the observation group was positive and approximately equal for both adjuvant treatment programs. Adjuvant chemoendocrine therapy for postmenopausal women appears to be justified due to an emerging OS advantage and increasing TWiST gained for the treated patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ganz, P. A., Kwan, L., Stanton, A. L., Krupnick, J. L., Rowland, J. H., Meyerowitz, B. E., Bower, J. E., & Belin, T. R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh060 · Cited by 505
Quality-of-life assessment in clinical trials
Gelber, R. D., & Gelber, S. (1995) · Cancer Treatment and Research · doi:10.1007/978-1-4615-2009-2_11 · Cited by 402
Self-citationShrestha, A., Martin, C., Burton, M., Walters, S., Collins, K., & Wyld, L. (2019) · Psycho-Oncology · doi:10.1002/pon.5054 · Cited by 381
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
Goldhirsch, A., Gelber, R. D., Simes, R. J., Glasziou, P., & Coates, A. S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.1.36 · Cited by 340
Self-citationQuality of Life in Cancer: Definition, Purpose, and Method of Measurement
Cella, D. F., & Tulsky, D. S. (1993) · Cancer Investigation · doi:10.3109/07357909309024860 · Cited by 333
Metadata
- Authors
- Gelber, R. D., & Goldhirsch, A.
- Venue
- Journal of Clinical Oncology
- Published
- 1986-12
- Volume
- 4
- Issue
- 12
- Pages
- 1772-1779
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2254058470
- Cited by
- 234
- References
- 0
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. https://app.cochat.ai/papers/10.1200/jco.1986.4.12.1772
- The paper
- Gelber, R. D., & Goldhirsch, A. (1986). A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1986.4.12.1772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.